Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.

In Canada, people diagnosed with active tuberculosis (TB) disease are routinely treated with isoniazid, rifampin, pyrazinamide and ethambutol. Although effective, the treatment is associated with significant adverse drug reactions (ADRs). Current knowledge of these ADRs has focused on their frequency and clinical natures [1, 2]. However, reporting clinical natures of ADRs is not adequate to fully reflect their impact on patients’ health status. In recent years, patientreported outcomes, such as health-related quality of life (HRQoL), are increasingly appreciated in evaluating the impact of illnesses and the effectiveness of medical interventions [3]. Therefore, we intended to investigate the impact of anti-TB treatment-induced ADRs on patients’ HRQoL and to examine the association between baseline HRQoL status and the likelihood of ADRs during the subsequent treatment.